
AstraZeneca Issues Recall for Select Airsupra Inhalers Due to Defect
May 30th, 2025 – AstraZeneca has issued a voluntary recall notice for select lots of its Airsupra (albuterol/budesonide) inhalers due to a potential defect that could impact medication delivery. Airsupra is a dual-action inhaler used to treat and prevent symptoms of asthma and chronic obstructive pulmonary disease (COPD). The pharmaceutical company